NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
₹7.55 Cr Tax Addition Sustained for Mukka Proteins; Partial Relief on ₹8.08 Cr
Mukka Proteins has received an appellate order for Assessment Year 2018-19, resulting in a mixed outcome. The Commissioner of Income Tax (Appeals) deleted additions worth ₹8.08 Cr (₹4.48 Cr in prior period income and ₹3.60 Cr in stock additions). However, an addition of ₹7.55 Cr related to alleged excess stock was sustained under Section 115BBE, which carries a high effective tax rate of 78%. Since the company has already paid tax at 34.94% on this amount, it faces a potential additional liability for the differential tax amount.
உச்சம் நம்பிக்கை
என்ன மாறியதுA legacy tax dispute from AY 2018-19 has reached the first appellate stage, resulting in the company winning relief on approximately 52% of the disputed additions while losing on the remainder.
ஏன் இது முக்கியம்The sustained addition of ₹7.55 Cr is subject to a punitive 78% tax rate; the potential additional tax liability (the delta between 78% and the 34.94% already paid) represents roughly 5.7% of the company's TTM PAT of ₹57 Cr.
📅 குறுகிய காலம்Neutral to slightly negative as the market weighs the benefit of the ₹8.08 Cr relief against the high-tax penalty on the sustained ₹7.55 Cr.
📈 நீண்ட காலம்Limited; this is a legacy tax matter from 2018 and does not impact the company's current operational capacity or growth strategy in Oman.
⚠ அபாய எச்சரிக்கைகள்
Potential additional tax outflow due to high effective tax rate under Section 115BBE
Continued litigation risk
👀 கவனிக்க வேண்டியவை
Monitor whether the company files a further appeal with the Income Tax Appellate Tribunal (ITAT) to contest the sustained ₹7.55 Cr addition and its associated high tax rate.
Mukka Proteins Acquires 51% Stake in Delta Marine Products for Rs 11.10 Crore
Mukka Proteins Limited has successfully completed the acquisition of a 51% controlling stake in Delta Marine Products, a partnership firm, for a total cash consideration of Rs 11.10 crore. The target entity is engaged in the manufacturing of fish meal and fish oil, which is the core business of Mukka Proteins. Delta Marine Products showed significant revenue growth, with turnover rising from Rs 3.64 crore in FY24 to Rs 28.17 crore in FY25, although it reported a marginal net loss of Rs 19.73 lakhs in the latest fiscal year. This strategic move is intended to expand production capacity and improve market reach through operational optimization.
முக்கிய அம்சங்கள்
Acquired 51% controlling stake in Delta Marine Products for a cash consideration of Rs 11.10 crore.Target entity's turnover increased by over 670% year-on-year to Rs 28.17 crore in FY 2024-25.The acquisition aligns with Mukka's core business of fish meal and fish oil manufacturing to drive capacity expansion.The transaction was completed on June 25, 2026, through capital contribution rather than a share swap.Target entity reported a net loss of Rs 19.73 lakhs in FY25, indicating a focus on turnaround through operational synergies.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic expansion move that adds significant top-line potential; however, they should monitor the company's ability to turn the target entity profitable through operational efficiencies.
Mukka Proteins to raise ₹47 Crore via preferential issue of 2 Crore convertible warrants
Mukka Proteins Limited has applied for in-principle approval from BSE and NSE to issue 2,00,00,000 convertible warrants on a preferential basis. The warrants are priced at ₹23.50 each, aiming to raise a total of ₹47 crore from 15 non-promoter investors. These warrants will be convertible into equity shares ranking pari-passu with existing shares. The issue is subject to shareholder and regulatory approvals, with the relevant date fixed as June 12, 2026.
முக்கிய அம்சங்கள்
Proposed issuance of 2,00,00,000 convertible warrants at an issue price of ₹23.50 per warrant.Total capital infusion of ₹47,00,00,000 (₹47 Crore) through the preferential route.Allottees consist entirely of non-promoter investors, including individuals and entities like Multiplex Capital Limited.The issue price was determined based on a valuation report from an Independent Registered Valuer.Post-issue, no individual allottee will exceed 5% of the company's fully diluted share capital.
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming shareholder meeting for approval and monitor how the company intends to utilize the ₹47 crore for growth. The issue price of ₹23.50 provides a significant valuation benchmark for the stock.
Mukka Proteins to Acquire 51% Stake in Delta Marine Products for Rs 11.10 Crore
Mukka Proteins Limited has approved a strategic investment to acquire a 51% controlling stake in Delta Marine Products, a partnership firm engaged in manufacturing fish meal and fish oil. The acquisition will cost up to Rs 11.10 crore, to be paid in cash through capital contributions in one or more tranches. While the target entity reported a significant turnover of Rs 28.17 crore in FY 2024-25, it recorded a net loss of Rs 19.73 lakhs. The transaction is expected to be completed by September 30, 2026, aiming to enhance Mukka's production capacity and market reach.
முக்கிய அம்சங்கள்
Acquisition of a 51% majority stake in Delta Marine Products for a consideration not exceeding Rs 11.10 crore.Target entity's turnover surged from Rs 3.64 crore in FY24 to Rs 28.17 crore in FY25, showing rapid scale-up.The deal is a strategic horizontal integration as both entities operate in the fish meal and fish oil industry.The acquisition is expected to be finalized by September 30, 2026, via cash-based capital contributions.Delta Marine Products reported a PAT loss of Rs 19.73 lakhs for FY 2024-25, which Mukka aims to improve through operational optimization.
👀 கவனிக்க வேண்டியவை
Investors should view this as a growth-oriented move that expands Mukka's core capacity, though they should monitor the company's ability to turn the target entity profitable. The rapid revenue growth of Delta Marine suggests strong market demand for its products.
Mukka Proteins to Raise ₹47 Cr via Warrants and Acquire 51% Stake in Two Firms for ₹26.1 Cr
Mukka Proteins Limited has approved a preferential issue of 2,00,00,000 fully convertible warrants at ₹23.50 per warrant, aiming to raise ₹47 crore from non-promoter investors. The company is simultaneously deploying capital to acquire 51% stakes in two partnership firms, Delta Marine Products and Aqua Marine, for ₹11.10 crore and ₹15 crore respectively. These strategic investments are focused on expanding the company's core fish meal and fish oil business and optimizing production efficiency. The warrants are convertible into equity shares within 18 months, which will eventually increase the company's paid-up equity capital to ₹32 crore.
முக்கிய அம்சங்கள்
Approved issuance of 2 crore fully convertible warrants at ₹23.50 each, aggregating to ₹47 crore.Acquiring 51% controlling stake in Delta Marine Products for a consideration up to ₹11.10 crore.Acquiring 51% controlling stake in Aqua Marine for a consideration up to ₹15.00 crore.Target entities Delta Marine and Aqua Marine reported FY25 turnovers of ₹28.17 crore and ₹32.15 crore respectively.The acquisitions are expected to be completed by September 30, 2026, to drive capacity expansion.
👀 கவனிக்க வேண்டியவை
Investors should view this as a growth-oriented move that expands the company's manufacturing footprint; however, they should monitor the post-acquisition integration and the impact on consolidated profitability.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CARE Downgrades Mukka Proteins to 'BBB-' Over Stretched Working Capital; Outlook Negative
CARE Ratings has downgraded Mukka Proteins' long-term bank facilities to 'BBB-' from 'BBB' while maintaining a 'Negative' outlook. The downgrade stems from a prolonged working capital cycle of 189 days and high inventory levels, which have led to a 95% utilization of bank limits. While FY26 revenue grew 45% to ₹1,468 crore, debt coverage metrics have weakened, with Total Debt/GCA rising to 10.84x from 7.35x. The company remains exposed to volatile fish meal prices and seasonal raw material availability.
முக்கிய அம்சங்கள்
Long-term rating downgraded to CARE BBB- (Negative) for ₹495 crore in bank facilities.Working capital cycle stood at 189 days in FY26, significantly higher than the historical <70 days.Revenue grew 45% YoY to ₹1,468 crore in FY26, but interest coverage dropped to 2.48x.Total Debt to Gross Cash Accruals (TD/GCA) deteriorated to 10.84x from 7.35x YoY.Average utilization of working capital limits reached 95%, indicating tight liquidity.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the downgrade reflects rising financial risk and liquidity pressure. Watch for a reduction in inventory levels and improvement in cash flows as key recovery signals.
Mukka Proteins Targets ₹3,000+ Cr Revenue by FY30; FY26 Revenue at ₹1,449 Cr
Mukka Proteins reported FY26 revenue of ₹1,449 crore and has set an ambitious target to exceed ₹3,000 crore by FY30, representing a 2x growth in four years. The company maintains a dominant 25-30% market share in the Indian fishmeal and fish oil segment, with exports contributing 79.7% of total revenue. Strategic diversification into insect protein and waste management is underway, supported by carbon credit approvals for 1,200 TPD and a ₹474.89 crore leachate treatment order. The company is also expanding its global footprint with a new facility in Oman and recent acquisitions to strengthen its wholly-owned subsidiaries.
முக்கிய அம்சங்கள்
FY26 Revenue reached ₹1,449 crore with a strategic target to reach ₹3,000+ crore by FY30Maintains a leading 25-30% market share in India's fishmeal and fish oil industry with 2,91,720 MT/year capacityExport-heavy business model with 79.7% of FY26 revenue coming from international markets across 25+ countriesDiversifying into waste management with a significant ₹474.89 crore leachate treatment contract from BSWMLSecured carbon credit approvals for 1,200 TPD, aligning with global ESG trends and potential valuation re-rating
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the new Oman facility and the scaling of the high-margin insect protein vertical. The ambitious FY30 revenue guidance and transition to an integrated protein platform suggest strong long-term growth potential.
Mukka Proteins FY26 Revenue Surges 44% to ₹1,449.5 Cr; Q4 PAT Jumps 52.6% YoY
Mukka Proteins reported a strong FY26 with consolidated revenue growing 44% YoY to ₹1,449.5 crore, supported by robust global demand and improved pricing. While full-year PAT grew 18.7% to ₹57.1 crore, the fourth quarter saw significant margin expansion with Q4 PAT rising 52.6% YoY to ₹21.4 crore. The company is aggressively scaling its global footprint with an upcoming facility in Oman and a new subsidiary in Sri Lanka. Strategic wins like the Bengaluru animal waste management contract and MarinTrust alignment further strengthen its ESG-led growth profile.
முக்கிய அம்சங்கள்
FY26 Revenue increased 44% YoY to ₹1,449.5 Cr, while EBITDA grew 30.9% to ₹145.3 Cr.Q4 FY26 EBITDA margins expanded by 421 bps YoY to 12.9%, leading to a 52.6% surge in quarterly PAT.Upcoming 21,249 sq. mt facility in Oman and new investment in Sri Lanka to drive international growth.Secured a strategic contract for integrated animal waste management in Bengaluru from BBMP/BSWML.Maintains a dominant 25-30% market share in India's fishmeal and fish oil segment.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning of the Oman facility and the execution of the Bengaluru waste contract as key growth catalysts. The significant margin improvement in Q4 suggests better operational efficiency and pricing power in the marine protein segment.
Mukka Proteins to Invest ₹2.5 Crore for 49% Stake in New Sri Lankan Entity
Mukka Proteins has approved the incorporation of a new overseas entity, Lanka Bio Proteins Private Limited, in Sri Lanka to expand its international footprint. The company will invest up to ₹2.5 crore (approximately 9.75 crore Sri Lankan Rupees) to acquire a 49% equity stake in the new venture. The entity will focus on the manufacturing and trading of marine products, aligning with Mukka's core business. The total proposed capital for the new entity is approximately ₹3.60 crore, with completion expected by December 31, 2026.
முக்கிய அம்சங்கள்
Investment of up to ₹2.5 crore for a 49% stake in the newly incorporated Sri Lankan entity.Total proposed capital of the target entity, Lanka Bio Proteins Private Limited, is ₹3.60 crore.The venture focuses on manufacturing and trading marine products and allied activities.Strategic move to expand international business operations and strengthen global presence.The acquisition and incorporation process is slated for completion by December 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of this international expansion as it could diversify revenue streams and enhance long-term growth. The relatively small investment size suggests a low-risk entry into the Sri Lankan market.
Mukka Proteins Board Approves Raising ₹75 Crores via Non-Convertible Debentures
The Board of Mukka Proteins has approved the issuance of secured, rated, and listed Non-Convertible Debentures (NCDs) totaling ₹75 crores. The fundraise is divided into two parts: an immediate ₹25 crore tranche with a 12% annual coupon and a 15-month tenure, and a broader ₹50 crore authorization for future tranches. These securities will be issued on a private placement basis and listed on the BSE Wholesale Debt Market. This move indicates a strategic push to secure debt capital, likely for working capital or expansion needs.
முக்கிய அம்சங்கள்
Total fundraise of ₹75 crores approved via secured, rated, and listed NCDs.First tranche of ₹25 crores carries a 12.00% annual coupon rate with monthly interest payments.The ₹25 crore NCDs have a short-term tenure of 15 months from the date of allotment.Additional ₹50 crores authorized to be raised in one or more tranches via private placement.NCDs will be secured against current assets or other company assets as per transaction documents.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's debt-to-equity ratio and ensure the 12% interest cost is offset by higher returns from the deployed capital. It is important to track the specific end-use of these funds in upcoming quarterly reports.
Mukka Proteins FY26 Revenue Up 39% to ₹1,229 Cr; Board OKs ₹75 Cr Fundraise & SL Expansion
Mukka Proteins reported a robust 39% YoY growth in annual revenue from operations, reaching ₹1,229.20 crore for FY26. The company's profit before tax also improved to ₹58.78 crore from ₹52.58 crore in the previous fiscal year. To support this growth, the board approved a total fundraise of ₹75 crore through Non-Convertible Debentures (NCDs). Additionally, the company is expanding its footprint with a new 49% stake in a Sri Lankan entity and a 51% stake in a domestic joint venture.
முக்கிய அம்சங்கள்
Annual revenue from operations grew 38.6% YoY to ₹1,229.20 crore in FY26 compared to ₹886.74 crore in FY25.Board approved fundraising of up to ₹75 crore via private placement of secured, rated, listed NCDs in two tranches.Strategic international expansion into Sri Lanka with an investment of up to ₹2.50 crore for a 49% stake in Lanka Bio Proteins.Standalone Profit Before Tax (PBT) for the full year ended March 31, 2026, stood at ₹58.78 crore.Approved a 51% profit-sharing investment in a new partnership firm named MPL FC HRC JV.
👀 கவனிக்க வேண்டியவை
The company is showing strong top-line growth and aggressive expansion plans; investors should monitor the successful execution of the Sri Lankan venture and the impact of new debt on the balance sheet.
Mukka Proteins Acquires 100% Stake in Haris Marine Products for Rs. 19.64 Lakhs
Mukka Proteins Limited has completed the acquisition of 2,000 equity shares of Haris Marine Products Private Limited (HMPPL), making it a wholly-owned subsidiary effective March 30, 2026. The acquisition was executed for a total cash consideration of Rs. 19.64 Lakhs. While HMPPL reported nil turnover for the last two financial years, it surprisingly recorded a Profit After Tax (PAT) of Rs. 2.24 Crores in FY 2024-25. This strategic move is intended to expand Mukka's core business in the fish meal and fish oil industry.
முக்கிய அம்சங்கள்
Acquired 2,000 equity shares at Rs. 100 face value for a total of Rs. 19.64 Lakhs.Haris Marine Products (HMPPL) has become a 100% Wholly Owned Subsidiary of Mukka Proteins.Target entity reported a PAT of Rs. 2.24 Crores for FY 2024-25 despite reporting nil turnover.HMPPL previously had a turnover of Rs. 50.95 Crores in FY 2022-23 before dropping to nil in subsequent years.The acquisition is a strategic investment to expand the company's core fish meal and fish oil business.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of this subsidiary and seek clarity on how the entity maintains high profitability despite nil turnover. The low acquisition cost relative to the target's PAT suggests a value-accretive deal for the parent company.
Mukka Proteins to Acquire Remaining 2% Stake in Haris Marine Products for ₹19.64 Lakhs
Mukka Proteins Limited has entered into a Share Purchase Agreement to acquire the remaining 2% equity stake in Haris Marine Products Private Limited. The company currently holds a 98% stake and will pay a total consideration of INR 19.64 Lakhs for the final 2,000 shares. This acquisition will make Haris Marine Products a wholly-owned subsidiary of Mukka Proteins. The transaction is a related party transaction involving the company's promoters but has been conducted at arm's length.
முக்கிய அம்சங்கள்
Acquisition of 2,000 equity shares representing the final 2% stake in Haris Marine ProductsTotal cash consideration for the transaction is INR 19.64 LakhsMukka Proteins' ownership in the subsidiary will increase from 98% to 100%The deal involves promoters as sellers and is executed at arm's length
👀 கவனிக்க வேண்டியவை
This is a minor consolidation of a subsidiary and has a negligible financial impact due to the small deal size. Investors should view it as a positive move towards simplifying the corporate structure.
Mukka Proteins Achieves MarinTrust Improver Programme Compliance for 3 Years
Mukka Proteins Limited has received a confirmation letter from Global Trust Certification (NSF) for compliance with the MarinTrust Improver Programme for Responsible Supply of Marine Ingredients. This certification, valid for a period of 3 years, recognizes the company's use of Fishery Improvement Project (FIP) raw materials. The compliance reinforces the company's commitment to sustainability, traceability, and responsible sourcing in its marine ingredient supply chain. This development is expected to strengthen buyer confidence and enhance the company's competitive positioning in global markets.
முக்கிய அம்சங்கள்
Compliance confirmed by Global Trust Certification Ltd, Ireland, for the MarinTrust Improver Programme.The certification is valid for a period of 3 years, ensuring long-term supply chain recognition.Enables the company to source marine ingredients produced using Fishery Improvement Project (FIP) raw materials.Provides assurance to global buyers regarding traceability and responsible sourcing practices.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive ESG development that improves the company's ability to cater to international markets with strict sustainability standards. Monitor if this certification leads to higher-margin export orders or new global partnerships.
Mukka Proteins Limited has finalized the acquisition of 1,000 equity shares of Ento Proteins Private Limited (EPPL) for a total cash consideration of Rs. 32.30 Lakhs. Following this transaction, EPPL has become a wholly-owned subsidiary of the company effective February 23, 2026. EPPL is a manufacturer of insect meal and insect oil, reporting a turnover of Rs. 7.46 Crores and a PAT of Rs. 49.47 Lakhs for FY 2024-25. This acquisition aligns with Mukka Proteins' strategic plan to expand its presence in the alternate proteins market.
முக்கிய அம்சங்கள்
Acquired 1,000 equity shares for a total cash consideration of Rs. 32.30 LakhsEnto Proteins (EPPL) is now a 100% wholly-owned subsidiary of Mukka ProteinsEPPL reported a turnover of Rs. 7.46 Crores and PAT of Rs. 49.47 Lakhs for FY 2024-25Target company specializes in the niche manufacturing of insect meal and insect oilStrategic expansion into the high-growth alternate proteins business segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of this niche alternate protein business and its contribution to the consolidated bottom line. The acquisition is small but strategically sound for long-term diversification.
Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for ₹32.3 Lakhs
Mukka Proteins Limited has entered into a Share Purchase Agreement (SPA) to acquire the remaining 25.99% equity stake in its subsidiary, Ento Proteins Private Limited. The company currently holds 74.01% of the investee company and will move to 100% ownership upon completion. The total cash consideration for the 1,000 equity shares is ₹32,30,000. This acquisition will result in Ento Proteins becoming a wholly-owned subsidiary and will terminate previous shareholder agreements.
முக்கிய அம்சங்கள்
Acquisition of remaining 25.99% stake in Ento Proteins Private LimitedTotal cash consideration of INR 32,30,000 for 1,000 equity sharesOwnership stake increases from 74.01% to 100%, making it a wholly-owned subsidiaryRescission and termination of the Shareholders’ Agreement dated September 7, 2021Transaction involves acquisition from Holocene Ecosolutions Private Limited
👀 கவனிக்க வேண்டியவை
This is a routine consolidation of a subsidiary which simplifies the corporate structure. Investors should view this as a minor positive move to gain full control over the investee company's operations.
Mukka Proteins Q3 Revenue Jumps 115% YoY; Bags ₹475 Cr Order for Waste Management
Mukka Proteins reported a robust Q3 FY26 with revenue surging 115% YoY to ₹653.5 crore, driven by strong export demand and operational scaling. The company secured a major ₹474.89 crore order for leachate treatment, marking a significant step in its waste-to-value diversification strategy. 9M FY26 revenue reached ₹1,068.9 crore, already exceeding the total FY25 revenue of ₹887 crore. Management has set an ambitious target of ₹2,500+ crore revenue by FY30, supported by capacity expansions and carbon credit initiatives.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 115% YoY to ₹653.5 crore; 9M FY26 revenue reached ₹1,068.9 crore.Secured a ₹474.89 crore order from BSWML for legacy leachate treatment over 4 years.Carbon credit portfolio advanced with 300 TPD operations listed on Verra Registry and expansion to 1,000 TPD approved.Board approved increasing stakes in Ento Proteins and Haris Marine Products to 100% ownership.Export revenue share stands at 75.7% for 9M FY26, with a 25-30% domestic market share.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the large waste management contract and the progress of carbon credit issuance, which could significantly boost margins. The company's aggressive FY30 revenue target suggests strong management confidence in the integrated protein and sustainability platform.
Mukka Proteins to Acquire Remaining 25.99% Stake in Ento Proteins for Rs 32.3 Lakhs
Mukka Proteins has approved the acquisition of an additional 1,000 equity shares in its subsidiary, Ento Proteins Private Limited (EPPL), for Rs 32.30 lakhs. This transaction will increase Mukka's stake from 74.01% to 100%, making EPPL a wholly-owned subsidiary. EPPL is a niche manufacturer of insect meal and insect oil, reporting a turnover of Rs 7.46 crore and a PAT of Rs 49.47 lakhs for FY 2024-25. The move is part of Mukka's strategic plan to expand its presence in the alternate proteins market.
முக்கிய அம்சங்கள்
Acquisition of 1,000 equity shares to increase shareholding from 74.01% to 100%Total cash consideration for the additional stake is Rs 32.30 lakhsEPPL turnover grew from Rs 4.72 crore in FY23 to Rs 7.46 crore in FY25Target entity EPPL reported a profit after tax (PAT) of Rs 49.47 lakhs in FY 2024-25The acquisition is expected to be completed by June 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should note this strategic consolidation in the high-growth alternate protein segment, which could provide long-term synergy benefits. The acquisition is priced reasonably relative to EPPL's profitability and revenue growth.
Mukka Proteins reported a robust 115% YoY increase in consolidated revenue for Q3 FY26, reaching ₹6,534.97 million. While revenue grew significantly, the profit attributable to shareholders saw a slight decline to ₹237.48 million compared to ₹262.61 million in the previous year's quarter, primarily due to higher minority interest shares. The company also announced the strategic acquisition of remaining stakes in Ento Proteins and Haris Marine Products, making them wholly-owned subsidiaries. These acquisitions aim to consolidate operations in the fish and insect protein segments.
முக்கிய அம்சங்கள்
Consolidated revenue from operations grew 115% YoY to ₹6,534.97 million in Q3 FY26.Consolidated Net Profit (PAT) for the quarter stood at ₹272.53 million, a significant recovery from ₹68.84 million in Q2 FY26.Board approved the acquisition of additional shares in Ento Proteins and Haris Marine Products to make them 100% subsidiaries.Nine-month revenue (9M FY26) reached ₹10,688.52 million, already surpassing the full-year FY25 revenue of ₹10,064.16 million.Finance costs increased to ₹145.61 million in Q3 FY26 compared to ₹109.07 million in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the massive top-line expansion and the strategic move to full ownership of subsidiaries, while monitoring if the bottom-line growth can catch up to revenue pace in future quarters.
Mukka Proteins Lists BSF Project on Verra Registry; Expands Capacity to 1,000 TPD
Mukka Proteins has achieved a significant milestone by listing its 300 TPD Black Soldier Fly (BSF) wet-waste processing project on the Verra Registry, paving the way for carbon credit (VCU) issuance. Furthermore, the company has received approval to expand this project's capacity from 300 TPD to 1,000 TPD within Bengaluru's waste management framework. This expansion is structured as a grouped project, allowing for phased inclusion of additional modules and progressively higher carbon credit generation. The move strengthens the company's revenue diversification through sustainable, circular-economy solutions.
முக்கிய அம்சங்கள்
BSF-based 300 TPD wet-waste project formally listed on Verra Registry under Project ID 5893Received incremental approval to expand processing capacity from 300 TPD up to 1,000 TPDProject follows ACM0022 methodology for Verified Carbon Standard (VCS) registrationMukka Proteins maintains a 25-30% market share in India's fishmeal and fish oil sectorTotal installed capacity across fishmeal and related products stands at 2,64,390 MT per year
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the 30-day public comment period and subsequent VCU issuance as a new high-margin revenue stream. The successful scaling to 1,000 TPD will be a key driver for long-term valuation in the ESG and waste-to-value segments.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
